Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10221126 Solabegron zwitterion and uses thereof

Patent 10221126 was granted and assigned to Velicept Therapeutics on March, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Velicept Therapeutics

0

Current Assignee

Velicept Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Raymond E. Stevens0

Bingidimi Itute Mobele0

Dalian Zhao0

Date of Patent

March 5, 2019

0

Patent Application Number

160189450

Date Filed

June 26, 2018

0

Patent Citations Received

US Patent 10668034 Pharmaceutical compositions and the treatment of overactive bladder

US Patent 10751311 Compositions and methods of using modified release solabegron for lower urinary tract symptoms

US Patent 10350182 Pharmaceutical compositions and the treatment of overactive bladder

Patent Primary Examiner

Nyeemah A Grazier

0

Patent abstract

This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10221126 Solabegron zwitterion and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool